Patent ID: 11884720
Assignee: AMGEN RESEARCH (MUNICH) GMBH
Field: Biotechnology (Chemistry)
Classification: CPC C  A | IPC C

Claim 7:
8. The bispecific antibody construct according to claim 1, wherein the second binding domain comprises
(a) a VL region comprising CDR-L1, CDR-L2 and CDR-L3 comprising:
(i) CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 20, CDR-L2 comprising the amino acid sequence set forth in SEQ ID 21 and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 22;
(ii) CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 65, CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 66 and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 67; or
(iii) CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 83, CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 84 and CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 85; and

(b) a VH region comprising CDR-L1, CDR-L2 and CDR-L3 comprising:
(i) CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 14, CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 15 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 16;
(ii) CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 23, CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 24 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 25;
(iii) CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 32, CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 33 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 34;
(iv) CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 66 of SEQ ID NO: 41, CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 42 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 43;
(v) CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 50, CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 51 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 52;
(vi) CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 59, CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 60 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 61;
(vii) CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 68, CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 69 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 70;
(viii) CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 77, CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 78 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 79;
(ix) CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 86, CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 87 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 88; or
(x) CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 95, CDR-H2 comprising the amino acid sequence set forth in SEQ ID NO: 96 and CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 97.